Skip to main content
Premium Trial:

Request an Annual Quote

Protagen, Bayer Partner on Biomarkers for Endometriosis

NEW YORK (GenomeWeb News) – Protagen today announced a collaboration with Bayer HealthCare Pharmaceuticals aimed at clinically validating diagnostic biomarkers for endometriosis.

The project is the third between the companies and builds on an endometriosis biomarker study performed last year. Protagen and Bayer initially partnered in 2008 to evaluate Protagen's UNIarray technology for patient stratification and predictive diagnosis of atrial fibrillation.

The current project will use the technology for the predictive diagnosis of endometriosis. Currently, the illness is diagnosed by laparoscopy.

Aside from endometriosis, the UNIarray technology is being applied to autoimmune diseases, chronic inflammatory diseases, and cancer. The firm's other partners include Biogen-Idec and SuppreMol, Peter Schulz-Knappe, chief scientific officer and executive vice president of diagnostics for Protagen, said in a statement.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.